Treatment of type 1 diabetes mellitus (T1DM) with continuous subcutaneous insulin infusion (CSII) can improve glycaemic control compared to that achieved by multiple-dose insulin therapy (MDI), with a lower incidence of hypoglycaemia and the same frequency of ketoacidosis. CSII is a viable treatment alternative for T1DM. A specialist in endocrinology or a paediatrician affiliated with a diabetes outpatient clinic should decide upon the indication. Initiation and control of CSII should take place at a limited number of facilities with trained specialist teams (minimally consisting of two endocrinologists or paediatricians, twc nurses with a special interest in CSII and a dietician). The CSII patients must undergo regular control and a possible future reevaluation of the indication by the trained team. Subjects on CSII need to be informed how to switch to MDI temporarily. A 24-hour telephone service should be available. The team shall undergo a systematic CSII training course. Ongoing quality control of the CSII should be established. Restrictive treatment indications should be retained. The current way of financing such treatment in Denmark is an obstacle to some patients' being offered it when appropriate.
|Bidragets oversatte titel||Continuous subcutaneous insylin infusion (CSII) in Denmark|
|Tidsskrift||Ugeskrift for laeger|
|Status||Udgivet - 11 okt. 2004|